Tryton Medical Revenue and Competitors
Estimated Revenue & Valuation
- Tryton Medical's estimated annual revenue is currently $3.9M per year.
- Tryton Medical's estimated revenue per employee is $125,500
- Tryton Medical's total funding is $104.3M.
Employee Data
- Tryton Medical has 31 Employees.
- Tryton Medical grew their employee count by 35% last year.
Tryton Medical Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $9.8M | 39 | 3% | N/A | N/A |
#2 | $15.1M | 60 | 7% | N/A | N/A |
#3 | $6M | 24 | 0% | N/A | N/A |
#4 | $24.8M | 99 | -12% | N/A | N/A |
#5 | $19.3M | 77 | 8% | N/A | N/A |
#6 | $28.1M | 112 | 20% | N/A | N/A |
#7 | $3.8M | 15 | -46% | N/A | N/A |
#8 | $19.3M | 77 | 4% | N/A | N/A |
#9 | $45.4M | 181 | 4% | N/A | N/A |
#10 | $6.8M | 27 | N/A | N/A | N/A |
What Is Tryton Medical?
Tryton Medical, Inc. is the leading developer of stents that are designed to definitively treat bifurcation lesions. 540,000 bifurcation coronary lesions are sub-optimally treated every year with a variety of time consuming and technically challenging procedures. No optimized solution exists for treating bifurcation lesions. As a result, cardiologists are forced to use a provisional strategy which avoids the deployment of a second stent – leaving the un-stented side branch vulnerable to thrombosis and restenosis. The ability to definitively treat bifurcation lesions will enable PCI-stenting to become the new standard of care for the treatment of left main coronary artery disease rather than bypass surgery.
keywords:N/A
$104.3M
Total Funding
31
Number of Employees
$3.9M
Revenue (est)
35%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Tryton Medical News
... Cardiovascular Systems Inc., Galt Medical, C.R. Bard, Angiodynamics, ACIST Medical Systems, Infraredx, Tryton Medical, B. Braun, Maquet.
Tryton Medical, Inc., a Durham, N.C.-based developer of stents designed to treat coronary bifurcation lesions, held an initial closing of an aggregate $20m private equity financing. Backers included existing investors RiverVest Venture Partners and 3×5 Special Opportunity Fund, new investor Can ...
Tryton’s Side Branch stent is made of a cobalt chromium alloy. It is placed in the side branch along with a conventional drug-eluting stent in the main vessel. “The company’s innovative stent system for coronary bifurcations is expected to be the first and only product of its kind to be approve ...
Tryton Medical, Inc., a Durham, N.C.-based developer of stents designed to treat bifurcation lesions, held an initial closing of an aggregate $24m financing. Backers included existing investors PTV Sciences, which led the round, RiverVest Venture Partners, Spray Venture Partners, and the 3×5 Sp ...
Other Companies in Durham
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4.8M | 31 | -6% | N/A |
#2 | N/A | 31 | 48% | N/A |
#3 | $3.7M | 31 | 0% | N/A |
#4 | $3.6M | 31 | 7% | N/A |
#5 | $4.8M | 31 | 11% | N/A |